非布索坦治疗痛风伴高尿酸血症的疗效及安全性  

Efficacy and safety of febuxostat in the treatment of gout with hyperuricemia

作　　者：贺玲玲[1] 俞勤凯 张兰玲[3] 彭杨茜子 徐霞[3] HE LingLing YU QinKai ZHANG LanLinga PENG YANG XiZia XU Xia(Department of Nephrology and Rheumatol- ogy, Sixth People＇s Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 201306, China Grade 2015 Graduate of Nanjing Medical University, Nanjing 210029, China Department of Rheumatology and Immunology, Changhai Hospital,Second Military Medical University,Shanghai 200433 ,China)

机构地区：[1]上海交通大学医学院附属第六人民医院肾脏风湿科,上海201306 [2]南京医科大学,2015级研究生南京210029 [3]第二军医大学长海医院风湿免疫科,上海200433

出　　处：《药学服务与研究》2017年第3期198-201,共4页Pharmaceutical Care and Research

摘　　要：目的:评价非布索坦治疗痛风伴有高尿酸血症患者的疗效及安全性。方法:2014年3月至2014年10月,第二军医大学长海医院风湿免疫科90例符合痛风伴高尿酸血症患者,随机分为别嘌醇300mg组、非布索坦40mg组和80mg组,每组各30例,观察疗效。第1个月联合口服美洛昔康7.5mg,1次/d,预防急性发作;每月随访1次,共6个月,期间常规方法测定肝、肾功能,血常规,血清尿酸,评估关节肿痛情况及胃肠道不适。结果:随访表明非布索坦80 mg治疗组血清尿酸≤0.36mmol/L的比例均高于其他两组,在服药后第6个月时,这种差别更显著,非布索坦80 mg组占83%,高于非布索坦40mg组的37%(P<0.01)和别嘌醇组的47%(P<0.01)。每次随访非布索坦80mg组血清尿酸下降幅度最高,且明显优于别嘌醇组(均P<0.05)。在随访的后两个月,非布索坦40mg组血清尿酸下降幅度均低于80mg组(P<0.05),别嘌醇组与非布索坦40mg组降尿酸效果基本相似(P>0.05),3组随访过程中不良反应无明显差别。结论:非布索坦80mg降尿酸能力优于别嘌醇300mg和非布索坦40mg。Objective：To evaluate the efficacy and safety of febuxostat in the treatment of gout with hyperuricemia.Methods：Ninety patients who sought medical care in the Department of Rheumatology and Immunology,Changhai Hospital of Second Military Medical University from March to October 2014 and conformed to the selection criteria of gout with hyperuricemia were randomly assigned to the 300 mg allopurinol group,the 40 mg febuxostat group and the 80 mg febuxostat group,each consisting of 30 patients.Then,close observations were made on the treatment efficacy.In the first month,oral meloxicam at a dosage of 7.5mg once a day was given to the patients of all the groups to prevent acute onset.All the patients had medical follow-ups once a month for a succession of 6months,during which liver and kidney functions,blood routine and serum urine acid were detected with conventional methods,and joint swelling and pain and gastrointestinal discomfort were evaluated.Results：Medical follow-ups indicated that the rate of urine acid less than 0.36mmol/L was obviously higher in the 80 mg febuxostat group,as compared with those of the 2other groups,and greater differences could be seen at month 6after medication,with the 80 mg febuxostat group accounting for 85%,which was significantly higher than those of the 40 mg febuxostat group（37%）and the allopurinol group（47%）（P0.01）.The results of every medical follow-up showed that the decreased rate of urine acid in the 80 mg febuxostat group was the highest and was obviously superior to that of the allopurinol group（P0.05）.In the last 2months of medical follow-ups,the decreased rates of urine acid in the 40 mg febuxostat group were all lower than those of the 80 mg febuxostat group（P0.05）.However,the decreased rates of urine acid in the 40 mg febuxostat group and the allopurinol group were fundamentally identical（P0.05）.There were no significant differences in the occurrence of adverse drug reactions for the 3groups during medical follow-up,when comparisons were mad

关 键 词：非布索坦 别嘌醇 痛风 高尿酸血症 药物疗法 

分 类 号：R971.1[医药卫生—药品]